IL17A and infection: While mice treated with gefitinib only had reduced levels of IL-1α and IL-17A at day 1 post infection, mice infected with either the ece1Δ/Δ mutant or the als1Δ/Δ als3Δ/Δ ece1Δ/Δ mutant had reduced levels of these cytokines at both days 1 and 2.